Bio-Rad Laboratories, Inc. (BIO-B) Balance Sheet
BIO-B balance sheet, 2025
December 31, 2025 · U.S. dollars$10.58B assets = $3.12B liabilities + $7.45B equity
Both columns are drawn to the same scale: what BIO-B owns equals what it owes plus shareholders’ equity. Hover a block for its value.
BIO-B financial health
Descriptive bands, not a rating. Fiscal 2025.
BIO-B balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $3.85B2016 | $10.58B2025 | +11.9%/yr | |
| Total liabilities | $1.27B2016 | $3.12B2025 | +10.5%/yr | |
| Shareholders’ equity | $2.58B2016 | $7.45B2025 | +12.5%/yr | |
| Cash & short-term investments | $839.4M2016 | $1.54B2025 | +7.0%/yr | |
| Total debt | $434.5M2016 | $1.53B2025 | +15.0%/yr | |
| Net cash (debt) | $404.9M2016 | $11.7M2025 | −$393.2M | |
| Working capital | $1.37B2016 | $2.39B2025 | +$1.0B | |
| Current ratio | 3.912016 | 5.622025 | +1.71 | |
| Debt / equity | 0.172016 | 0.212025 | +0.04 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BIO-B assets
BIO-B liabilities and equity
BIO-B debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
BIO-B balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $1.54B | $1.66B | $1.61B | $1.79B | $869.9M | $991.1M | $1.11B | $844.8M | $755.0M | $839.4M |
| Cash & equivalents | $531.8M | $488.1M | $403.8M | $434.2M | $470.8M | $662.2M | $660.7M | $431.5M | $383.8M | $456.3M |
| Short-term investments | $1.01B | $1.18B | $1.20B | $1.36B | $399.1M | $328.9M | $454.0M | $413.3M | $371.2M | $383.2M |
| Receivables | $472.5M | $452.5M | $489.0M | $494.6M | $423.5M | $419.4M | $392.7M | $392.4M | $464.8M | $372.3M |
| Inventory | $740.7M | $760.0M | $780.5M | $719.3M | $572.2M | $622.3M | $554.0M | $583.8M | $594.8M | $525.0M |
| Other current assets | $150.3M | $153.3M | $171.7M | $153.3M | $124.8M | $107.0M | $118.8M | $202.4M | $162.0M | $107.8M |
| Total current assets | $2.91B | $3.03B | $3.05B | $3.16B | $1.99B | $2.14B | $2.18B | $2.02B | $1.98B | $1.84B |
| Property, plant & equipment (net) | $709.9M | $688.6M | $723.7M | $679.6M | $716.4M | $693.5M | $701.2M | $508.7M | $493.5M | $488.6M |
| Goodwill & intangible assets | $754.1M | $704.1M | $734.1M | $738.6M | $601.2M | $491.4M | $409.6M | $352.9M | $680.2M | $638.7M |
| Long-term investments | $6.10B | $4.84B | $7.70B | $8.83B | $14.39B | $9.56B | $4.64B | $2.66B | $1.03B | $830.8M |
| Other non-current assets | $102.7M | $101.9M | $94.9M | $94.6M | $104.3M | $86.7M | $79.7M | $70.3M | $94.9M | $47.9M |
| Total assets | $10.58B | $9.36B | $12.30B | $13.50B | $17.80B | $12.97B | $8.01B | $5.61B | $4.27B | $3.85B |
| Liabilities | ||||||||||
| Accounts payable | $129.0M | $122.3M | $144.6M | $135.0M | $141.9M | $139.5M | $107.0M | $122.5M | $135.2M | $133.1M |
| Short-term debt | $37.9M | $42.9M | $40.9M | $36.8M | $36.9M | $38.3M | $461.6M | $493,000 | $420,000 | $334,000 |
| Deferred revenue | — | — | $35.76B | $52.2M | $50.9M | $42.5M | $33.7M | $26.9M | $28.2M | $31.0M |
| Total current liabilities | $517.0M | $467.8M | $522.8M | $568.7M | $680.9M | $631.5M | $905.5M | $450.8M | $502.7M | $471.3M |
| Long-term debt | $1.20B | $1.20B | $1.20B | $1.20B | $10.5M | $12.3M | $13.6M | $438.9M | $434.6M | $434.2M |
| Lease obligations | $181.8M | $173.1M | $205.9M | $189.9M | $212.4M | $211.6M | $211.4M | — | — | — |
| Other long-term liabilities | $1.40B | $1.13B | $1.84B | $2.12B | $3.42B | $2.45B | $1.33B | $701.0M | $405.5M | $365.8M |
| Total liabilities | $3.12B | $2.79B | $3.56B | $3.89B | $4.11B | $3.09B | $2.25B | $1.59B | $1.34B | $1.27B |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | — | — | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 |
| Retained earnings (deficit) | $8.18B | $7.42B | $9.26B | $9.90B | $13.53B | $9.27B | $5.47B | $3.72B | $1.83B | $1.83B |
| Treasury stock | — | — | — | −$263.6M | −$106.3M | −$99.9M | −$38.4M | −$49.1M | −$217,000 | −$101,000 |
| Accumulated other comprehensive income | −$189.1M | −$538.2M | −$336.0M | −$466.8M | −$175.6M | $282.5M | −$87.3M | −$47.0M | $738.8M | $417.8M |
| Total shareholders' equity | $7.45B | $6.57B | $8.74B | $9.62B | $13.69B | $9.88B | $5.76B | $4.02B | $2.93B | $2.58B |
| Key figures | ||||||||||
| Total debt | $1.53B | $1.37B | $1.41B | $1.39B | $223.4M | $225.7M | $651.2M | $439.4M | $435.0M | $434.5M |
| Net cash (debt) | $11.7M | $289.8M | $201.6M | $402.6M | $646.5M | $765.4M | $463.5M | $405.4M | $320.0M | $404.9M |
| Working capital | $2.39B | $2.56B | $2.53B | $2.59B | $1.31B | $1.51B | $1.27B | $1.57B | $1.47B | $1.37B |
| Tangible book value | $6.70B | $5.87B | $8.01B | $8.88B | $13.08B | $9.39B | $5.35B | $3.67B | $2.25B | $1.94B |
| Current ratio | 5.62 | 6.48 | 5.83 | 5.55 | 2.92 | 3.39 | 2.41 | 4.49 | 3.93 | 3.91 |
| Quick ratio | 3.90 | 4.53 | 4.01 | 4.02 | 1.90 | 2.23 | 1.66 | 2.74 | 2.43 | 2.57 |
| Debt / equity | 0.21 | 0.21 | 0.16 | 0.14 | 0.02 | 0.02 | 0.11 | 0.11 | 0.15 | 0.17 |
| Equity / assets | 70.5% | 70.2% | 71.1% | 71.2% | 76.9% | 76.2% | 71.9% | 71.7% | 68.6% | 67.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $1.62B | $1.56B | $1.54B | $1.42B | $1.37B | $1.66B | $1.66B | $1.62B | $1.62B | $1.65B | $1.61B | $1.76B |
| Cash & equivalents | $517.0M | $507.2M | $531.8M | $397.8M | $369.3M | $521.4M | $488.1M | $410.4M | $406.9M | $433.3M | $403.8M | $457.9M |
| Short-term investments | $1.10B | $1.06B | $1.01B | $1.02B | $1.00B | $1.14B | $1.18B | $1.21B | $1.21B | $1.21B | $1.20B | $1.30B |
| Receivables | $441.8M | $426.2M | $472.5M | $474.2M | $469.9M | $424.7M | $452.5M | $461.9M | $445.5M | $444.8M | $489.0M | $457.4M |
| Inventory | $780.6M | $770.5M | $740.7M | $783.2M | $798.8M | $790.1M | $760.0M | $804.3M | $803.7M | $783.4M | $780.5M | $775.8M |
| Other current assets | $179.6M | $180.7M | $150.3M | $164.0M | $168.6M | $161.4M | $153.3M | $166.9M | $190.9M | $187.1M | $171.7M | $154.6M |
| Total current assets | $3.02B | $2.94B | $2.91B | $2.84B | $2.81B | $3.04B | $3.03B | $3.06B | $3.06B | $3.06B | $3.05B | $3.15B |
| Property, plant & equipment (net) | $671.9M | $689.4M | $709.9M | $720.5M | $740.1M | $681.7M | $688.6M | $719.2M | $715.2M | $711.3M | $723.7M | $711.4M |
| Goodwill & intangible assets | $734.3M | $743.9M | $754.1M | $967.1M | $978.5M | $710.7M | $704.1M | $722.4M | $719.2M | $726.4M | $734.1M | $721.2M |
| Long-term investments | $5.72B | $5.31B | $6.10B | $5.06B | $5.58B | $4.99B | $4.84B | $6.00B | $5.10B | $8.02B | $7.70B | $7.22B |
| Other non-current assets | $101.7M | $102.8M | $102.7M | $109.0M | $107.9M | $103.7M | $101.9M | $103.6M | $98.2M | $92.9M | $94.8M | $98.4M |
| Total assets | $10.25B | $9.79B | $10.58B | $9.70B | $10.21B | $9.53B | $9.36B | $10.60B | $9.69B | $12.61B | $12.30B | $11.90B |
| Liabilities | ||||||||||||
| Accounts payable | $143.5M | $133.1M | $129.0M | $128.8M | $139.3M | $137.9M | $122.3M | $122.2M | $126.7M | $102.8M | $144.6M | $111.9M |
| Short-term debt | $400.7M | $436.7M | $37.9M | $38.1M | $40.6M | $42.5M | $42.9M | $44.1M | $42.0M | $40.5M | $40.9M | $39.6M |
| Deferred revenue | — | — | — | — | — | — | $400,000 | −$268.2M | −$126.7M | $34.0M | $35.76B | −$111.9M |
| Total current liabilities | $961.3M | $917.0M | $517.0M | $522.3M | $548.9M | $506.6M | $467.8M | $497.9M | $487.0M | $466.2M | $522.8M | $558.2M |
| Long-term debt | $803.0M | $802.9M | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.19B | $1.19B | $1.20B | $1.20B |
| Lease obligations | $166.7M | $174.8M | $181.8M | $192.6M | $204.1M | $167.6M | $173.1M | $186.8M | $202.4M | $209.8M | $205.9M | $216.5M |
| Other long-term liabilities | $1.31B | $1.22B | $1.40B | $1.24B | $1.34B | $1.14B | $1.13B | $1.42B | $1.23B | $1.90B | $1.84B | $1.72B |
| Total liabilities | $3.08B | $2.94B | $3.12B | $2.96B | $3.09B | $2.85B | $2.79B | $3.12B | $2.91B | $3.56B | $3.56B | $3.48B |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | — | — | — | — | — | — | — | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 |
| Retained earnings (deficit) | $8.02B | $7.65B | $8.18B | $7.46B | $7.80B | $7.48B | $7.42B | $8.13B | $7.48B | $9.64B | $9.26B | $8.91B |
| Accumulated other comprehensive income | −$271.3M | −$235.4M | −$189.1M | −$166.8M | −$154.1M | −$409.8M | −$538.2M | −$315.3M | −$451.4M | −$426.0M | −$336.0M | −$497.6M |
| Total shareholders' equity | $7.17B | $6.85B | $7.45B | $6.74B | $7.13B | $6.68B | $6.57B | $7.49B | $6.78B | $9.05B | $8.74B | $8.42B |
| Key figures | ||||||||||||
| Total debt | $1.20B | $1.38B | $1.53B | $1.40B | $1.41B | $1.37B | $1.37B | $1.39B | $1.39B | $1.40B | $1.41B | $1.41B |
| Net cash (debt) | $414.8M | $186.5M | $11.7M | $25.3M | −$32.7M | $290.9M | $289.8M | $234.3M | $223.4M | $245.9M | $201.7M | $353.5M |
| Working capital | $2.06B | $2.03B | $2.39B | $2.32B | $2.26B | $2.53B | $2.56B | $2.56B | $2.57B | $2.59B | $2.53B | $2.59B |
| Tangible book value | $6.44B | $6.11B | $6.70B | $5.77B | $6.15B | $5.97B | $5.87B | $6.77B | $6.06B | $8.32B | $8.01B | $7.69B |
| Current ratio | 3.14 | 3.21 | 5.62 | 5.44 | 5.12 | 5.99 | 6.48 | 6.14 | 6.28 | 6.57 | 5.83 | 5.64 |
| Quick ratio | 2.14 | 2.17 | 3.90 | 3.63 | 3.36 | 4.12 | 4.53 | 4.19 | 4.23 | 4.48 | 4.01 | 3.97 |
| Debt / equity | 0.17 | 0.20 | 0.21 | 0.21 | 0.20 | 0.21 | 0.21 | 0.19 | 0.21 | 0.15 | 0.16 | 0.17 |
| Equity / assets | 70.0% | 70.0% | 70.5% | 69.5% | 69.8% | 70.1% | 70.2% | 70.6% | 70.0% | 71.8% | 71.1% | 70.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 13, 2026); data from EODHD.
BIO-B financial position
At the end of fiscal 2025 (December 31, 2025), Bio-Rad Laboratories had total assets of $10.6 billion (up 12.9% from a year earlier), total liabilities of $3.1 billion and shareholders' equity of $7.5 billion. It held $1.5 billion in cash and short-term investments against $1.5 billion of debt, a net cash position of $11.7 million. Its current ratio was 5.62. In the latest quarter (ended June 30, 2026) total assets were $10.3 billion and equity $7.2 billion.
Related: BIO-B income statement, BIO-B cash flow statement, BIO-B key metrics. See the BIO-B stock overview for the latest quote and news.
BIO-B balance sheet FAQ
What are Bio-Rad Laboratories's total assets?
Bio-Rad Laboratories reported total assets of $10.6 billion at the end of fiscal 2025 (December 31, 2025), compared with $9.4 billion a year earlier.
How much debt does Bio-Rad Laboratories have?
Bio-Rad Laboratories had $1.5 billion of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.21.
How much cash does Bio-Rad Laboratories have?
Bio-Rad Laboratories held $1.5 billion in cash and short-term investments at the end of fiscal 2025; with $1.5 billion of debt that is net cash of $11.7 million.
What is Bio-Rad Laboratories's book value?
Bio-Rad Laboratories's shareholders' equity (book value) was $7.5 billion at the end of fiscal 2025.
What is Bio-Rad Laboratories's current ratio?
Bio-Rad Laboratories had current assets of $2.9 billion and current liabilities of $517.0 million, a current ratio of 5.62 (it can cover its short-term obligations).
How much goodwill does Bio-Rad Laboratories have?
Bio-Rad Laboratories carried $754.1 million of goodwill and intangible assets, 7.1% of total assets, at the end of fiscal 2025.